The main ingredient of this product is bivalirudin.

Chemical Name: D-phenylalanyl-L-prolyl-L-arginyl-L-prolyl-glycyl-glycyl-glycyl-glycyl-L-asparagyl-glycyl-L-aspartyl-L-phenylalanyl-L-glutamyl-L-glutamyl-L-isoleucyl-L-prolyl-L-glutamyl-L-glutamyl-L-tyrosyl-L-leucine

Chemical Structure

Molecular Formula: C₉₈H₁₃₈N₂₄O₃₃

Molecular Weight: 2180.28
Excipient: Mannitol, Sodium Hydroxid

This product is white loose or amorphous solid, extremely hygroscopic

It is indicated for use as an anticoagulant in patients undergoing percutaneous coronary intervention (PCI)

This product is used for intravenous injection and intravenous infusion.

The recommended dose of Bivalirudin is an intravenous bolus dose of 0.75 mg/kg before PCI, followed immediately by an infusion of 1.75 mg/kg/h for the duration of the PCI procedure (not more than 4 hours). Five minutes after the bolus dose has been administered, an activated clotting time (ACT) should be performed and an additional bolus of 0.3 mg/kg should be given if needed. After 4 hours, an additional IV infusion of Bivalirudin may be initiated at a rate 0.2 mg/kg/h (low-rate infusion), for up to 20 hours, if needed. Glycoprotein IIb/IIIa inhibitor (GPI) should be considered in the event that any of the conditions listed in the Replace-2 clinical trial (see Clinical Trials) is present. For patients with HIT/HITTS undergoing PCI, the recommended dose of Bivalirudin is an IV bolus of 0.75 mg/kg. This should be followed by a continuous intravenous infusion at a rate of 1.75 mg/kg/h for the duration of PCI procedure. Bivalirudin is recommended for use with aspirin (300-325 mg per day).